Losses narrow at MediGene but still no deal for EndoTAG-1
This article was originally published in Scrip
Executive Summary
MediGene reported a reduced net loss for 2009, from around €31 million to €22 million, on unchanged revenues of about $40 million. The German biotech company is still waiting to sign a much-needed partnership for its lead development candidate EndoTAG-1 but it hopes to increase revenue for 2010 through product sales alone.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.